[
  {
    "ts": "2025-10-01T15:48:25+00:00",
    "headline": "‘This team is guided by science’: Kenvue chief hits back at Trump and RFK Jr.’s Tylenol autism claims in memo to 20,000 employees",
    "summary": "Promotion of unproven claims from President Trump and RFK Jr. linking acetaminophen (Tylenol) to autism have significantly impacted Kenvue’s business.",
    "url": "https://finance.yahoo.com/news/team-guided-science-kenvue-chief-154825326.html",
    "source": "Fortune",
    "provider": "yfinance",
    "raw": {
      "id": "ad86c2f3-e4fc-3c3b-a3fc-4bfa61fd8f9f",
      "content": {
        "id": "ad86c2f3-e4fc-3c3b-a3fc-4bfa61fd8f9f",
        "contentType": "STORY",
        "title": "‘This team is guided by science’: Kenvue chief hits back at Trump and RFK Jr.’s Tylenol autism claims in memo to 20,000 employees",
        "description": "",
        "summary": "Promotion of unproven claims from President Trump and RFK Jr. linking acetaminophen (Tylenol) to autism have significantly impacted Kenvue’s business.",
        "pubDate": "2025-10-01T15:48:25Z",
        "displayTime": "2025-10-01T15:48:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/fortune_175/461689e9e45426f24a3acd08fc332def",
          "originalWidth": 2048,
          "originalHeight": 1366,
          "caption": "Kenvue interim CEO Kirk Perry.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SoNl2ELqh4oNOHdYOMYtng--~B/aD0xMzY2O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/461689e9e45426f24a3acd08fc332def.cf.webp",
              "width": 2048,
              "height": 1366,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZZsHelfmljb2pxOICjUQLA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/fortune_175/461689e9e45426f24a3acd08fc332def.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Fortune",
          "url": "http://fortune.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/team-guided-science-kenvue-chief-154825326.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/team-guided-science-kenvue-chief-154825326.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T08:44:00+00:00",
    "headline": "Should You Buy Kenvue Stock After Its 30% Plunge?",
    "summary": "There hasn't been much good news lately for this Johnson & Johnson spinoff.",
    "url": "https://www.fool.com/investing/2025/10/01/should-you-buy-kenvue-stock-after-its-30-plunge/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e6894c0b-cb16-368c-a81b-0d6e7c9f2395",
      "content": {
        "id": "e6894c0b-cb16-368c-a81b-0d6e7c9f2395",
        "contentType": "STORY",
        "title": "Should You Buy Kenvue Stock After Its 30% Plunge?",
        "description": "",
        "summary": "There hasn't been much good news lately for this Johnson & Johnson spinoff.",
        "pubDate": "2025-10-01T08:44:00Z",
        "displayTime": "2025-10-01T08:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/c41f6837d50504f785fb7587e15eec7e",
          "originalWidth": 1400,
          "originalHeight": 911,
          "caption": "A person with eyes closed and hands behind head while sitting in front of a monitor showing a stock chart.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l7KxMTdcj1mZ3m.oJ4mDrw--~B/aD05MTE7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/c41f6837d50504f785fb7587e15eec7e.cf.webp",
              "width": 1400,
              "height": 911,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nVxEWcgNlxbEzUNdHI1KyA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c41f6837d50504f785fb7587e15eec7e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/01/should-you-buy-kenvue-stock-after-its-30-plunge/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-kenvue-stock-30-plunge-084400387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]